|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,298.00 GBX | +2.85% |
|
+2.69% | +8.17% |
| 06-03 | EARNINGS AND TRADING: Vaultz Capital ousts CEO Benz, promotes Wood | AN |
| 06-03 | The Biotech Growth Trust PLC Reports Earnings Results for the Full Year Ended March 31, 2026 | CI |
| Fiscal Period: March | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | -23.18 | -5.82 | 12.39 | -15.6 | 31.17 | |||||
Return on Total Capital | -23.69 | -5.91 | 12.6 | -15.81 | 31.98 | |||||
Return On Equity % | -40.66 | -11.4 | 21.57 | -28.38 | 51.78 | |||||
Return on Common Equity | -40.66 | -11.4 | 21.57 | -28.38 | 51.78 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 100 | 100 | 100 | 100 | 100 | |||||
SG&A Margin | 2.53 | -13.18 | 4.79 | -4.82 | 2.32 | |||||
EBITA Margin % | 97.47 | 113.18 | 95.21 | 104.82 | 97.68 | |||||
EBIT Margin % | 97.47 | 113.18 | 95.21 | 104.82 | 97.68 | |||||
Income From Continuing Operations Margin % | 98.77 | 127.4 | 92.85 | 108.79 | 96.47 | |||||
Net Income Margin % | 98.77 | 127.4 | 92.85 | 108.79 | 96.47 | |||||
Net Avail. For Common Margin % | 98.77 | 127.4 | 92.85 | 108.79 | 96.47 | |||||
Normalized Net Income Margin | 61.68 | 79.51 | 58.15 | 67.88 | 60.31 | |||||
Levered Free Cash Flow Margin | 68.33 | 47.31 | 32.45 | 44.35 | 54.25 | |||||
Unlevered Free Cash Flow Margin | 68.27 | 45.78 | 33.32 | 43.26 | 54.78 | |||||
Asset Turnover | ||||||||||
Asset Turnover | -0.38 | -0.08 | 0.21 | -0.24 | 0.51 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 0 | 0.11 | 0.33 | 1.56 | 0.54 | |||||
Quick Ratio | - | 0.11 | 0.33 | 1.56 | 0.54 | |||||
Operating Cash Flow to Current Liabilities | -0.37 | -0.19 | -0.08 | -0.94 | -0.24 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 8.05 | 6.11 | 13.03 | - | 4.37 | |||||
Total Debt / Total Capital | 7.45 | 5.76 | 11.53 | - | 4.19 | |||||
Total Liabilities / Total Assets | 7.78 | 8.38 | 12.18 | 2.39 | 6.72 | |||||
EBIT / Interest Expense | -1.14K | -46.33 | 68.61 | -60.1 | 115.79 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | -192.27 | -84.18 | -347.85 | -194.56 | -277.7 | |||||
Gross Profit, 1 Yr. Growth % | -192.27 | -84.18 | -347.85 | -194.56 | -277.7 | |||||
EBITA, 1 Yr. Growth % | -201.22 | -81.63 | -308.48 | -204.11 | -265.61 | |||||
EBIT, 1 Yr. Growth % | -201.22 | -81.63 | -308.48 | -204.11 | -265.61 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | -200.99 | -79.6 | -280.64 | -210.81 | -257.58 | |||||
Net Income, 1 Yr. Growth % | -200.99 | -79.6 | -280.64 | -210.81 | -257.58 | |||||
Normalized Net Income, 1 Yr. Growth % | -200.85 | -79.61 | -281.27 | -210.38 | -257.89 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | -197.59 | -79.01 | -301.92 | -226.72 | -312.75 | |||||
Accounts Receivable, 1 Yr. Growth % | - | - | 2.88K | - | - | |||||
Total Assets, 1 Yr. Growth % | -34.19 | -15.66 | 14.12 | -44.92 | 33.37 | |||||
Tangible Book Value, 1 Yr. Growth % | -34.46 | -16.21 | 9.39 | -38.78 | 27.45 | |||||
Common Equity, 1 Yr. Growth % | -34.46 | -16.21 | 9.39 | -38.78 | 27.45 | |||||
Cash From Operations, 1 Yr. Growth % | 113.98 | -51.49 | -28 | 19.95 | -4.93 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -200.45 | -89.05 | -270 | -229.24 | -317.39 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -200.29 | -89.39 | -280.36 | -222.78 | -325.04 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 72.42 | -61.8 | -37.39 | 53.09 | 29.63 | |||||
Gross Profit, 2 Yr. CAGR % | 72.42 | -61.8 | -37.39 | 53.09 | 29.63 | |||||
EBITA, 2 Yr. CAGR % | 75.77 | -56.88 | -38.12 | 47.33 | 31.31 | |||||
EBIT, 2 Yr. CAGR % | 75.77 | -56.88 | -38.12 | 47.33 | 31.31 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 82.31 | -54.61 | -39.29 | 41.48 | 32.14 | |||||
Net Income, 2 Yr. CAGR % | 82.31 | -54.61 | -39.29 | 41.48 | 32.14 | |||||
Normalized Net Income, 2 Yr. CAGR % | 81.95 | -54.65 | -39.21 | 41.45 | 32.01 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 90.31 | -54.74 | -34.9 | 59.96 | 64.2 | |||||
Accounts Receivable, 2 Yr. CAGR % | - | -67.9 | - | - | -12.93 | |||||
Total Assets, 2 Yr. CAGR % | 3.22 | -25.5 | -1.89 | -20.71 | -14.29 | |||||
Tangible Book Value, 2 Yr. CAGR % | 3.84 | -25.9 | -4.26 | -18.16 | -11.67 | |||||
Common Equity, 2 Yr. CAGR % | 3.84 | -25.9 | -4.26 | -18.16 | -11.67 | |||||
Cash From Operations, 2 Yr. CAGR % | 95.24 | 1.89 | -40.9 | -7.07 | 6.78 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 119.97 | -66.83 | -56.85 | 48.22 | 67.62 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 118.52 | -67.38 | -56.26 | 48.81 | 66.22 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 91.81 | -22.24 | -28.75 | -28.16 | 60.89 | |||||
Gross Profit, 3 Yr. CAGR % | 91.81 | -22.24 | -28.75 | -28.16 | 60.89 | |||||
EBITA, 3 Yr. CAGR % | 101.31 | -17.21 | -27.09 | -26.4 | 53.18 | |||||
EBIT, 3 Yr. CAGR % | 101.31 | -17.21 | -27.09 | -26.4 | 53.18 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 112.48 | -12.14 | -28.07 | -25.81 | 46.65 | |||||
Net Income, 3 Yr. CAGR % | 112.48 | -12.14 | -28.07 | -25.81 | 46.65 | |||||
Normalized Net Income, 3 Yr. CAGR % | 111.81 | -12.28 | -28.03 | -25.83 | 46.73 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 132.7 | -8.74 | -25.5 | -18.72 | 75.92 | |||||
Accounts Receivable, 3 Yr. CAGR % | - | -41.98 | 45.35 | - | 182.67 | |||||
Total Assets, 3 Yr. CAGR % | -0.29 | -3.5 | -14.12 | -19.06 | -5.71 | |||||
Tangible Book Value, 3 Yr. CAGR % | -1.21 | -3.33 | -15.62 | -17.52 | -5.14 | |||||
Common Equity, 3 Yr. CAGR % | -1.21 | -3.33 | -15.62 | -17.52 | -5.14 | |||||
Cash From Operations, 3 Yr. CAGR % | 40.27 | 22.74 | -9.25 | -25.17 | -6.36 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 91.01 | -19.08 | -42.81 | -37.8 | 68.41 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 89.36 | -20.29 | -42.32 | -38.3 | 70.81 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 14.16 | 3.75 | 22.57 | 1.96 | -9.48 | |||||
Gross Profit, 5 Yr. CAGR % | 14.16 | 3.75 | 22.57 | 1.96 | -9.48 | |||||
EBITA, 5 Yr. CAGR % | 14.59 | 2.82 | 25.59 | 4.26 | -7.74 | |||||
EBIT, 5 Yr. CAGR % | 14.59 | 2.82 | 25.59 | 4.26 | -7.74 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 15.54 | 6.76 | 28.73 | 6.3 | -8.26 | |||||
Net Income, 5 Yr. CAGR % | 15.54 | 6.76 | 28.73 | 6.3 | -8.26 | |||||
Normalized Net Income, 5 Yr. CAGR % | 15.46 | 6.9 | 28.56 | 6.2 | -8.27 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 23.28 | 13.96 | 39.8 | 14.23 | 2.2 | |||||
Accounts Receivable, 5 Yr. CAGR % | - | 4.7 | 226.67 | - | 18.41 | |||||
Total Assets, 5 Yr. CAGR % | -1.52 | -4.17 | -0.94 | -10.79 | -14.19 | |||||
Tangible Book Value, 5 Yr. CAGR % | -2.49 | -4.57 | -2.44 | -9.56 | -14.06 | |||||
Common Equity, 5 Yr. CAGR % | -2.49 | -4.57 | -2.44 | -9.56 | -14.06 | |||||
Cash From Operations, 5 Yr. CAGR % | 18.1 | 7.49 | -0.73 | 9.82 | -3.15 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 19.09 | 0.14 | 5.35 | 3.09 | -12.08 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 19 | -0.11 | 5.37 | 2.32 | -11.92 |
- Stock Market
- Stocks
- BIOG Stock
- Financials The Biotech Growth Trust PLC
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















